New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVilon vs Pancragen

Vilon vs Pancragen

Side-by-side comparison of key properties, dosing, and research.

Immune SupportAnti-Aging & Longevity
Vilon
Anti-Aging & Longevity
Pancragen
Summary
Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Half-Life
Very short as a free dipeptide; effects mediated via gene regulation
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, Oral
SubQ, Oral
Research
Typical Dose
1–2 mg SC daily or 5–10 mg oral daily
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Immune system modulation and restoration
  • Lifespan extension (30–40% in animal studies)
  • T-cell and NK-cell activation
  • Epigenetic anti-aging activity
  • Reduces oxidative stress markers
  • Antioxidant gene upregulation
  • May prevent age-related immune senescence
  • Anti-tumor immune surveillance
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
Side Effects
  • Excellent safety profile, decades of Russian clinical use
  • Rare: mild injection site reaction
  • Very rare: mild allergic reaction
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
Stacks With